Moors & Cabot Inc. Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Moors & Cabot Inc. boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 18.2% in the third quarter, Holdings Channel reports. The institutional investor owned 54,469 shares of the company’s stock after acquiring an additional 8,390 shares during the quarter. Moors & Cabot Inc.’s holdings in Moderna were worth $3,640,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of MRNA. Advisors Asset Management Inc. increased its holdings in shares of Moderna by 25.8% in the third quarter. Advisors Asset Management Inc. now owns 4,740 shares of the company’s stock worth $317,000 after purchasing an additional 971 shares during the period. Commerce Bank increased its stake in Moderna by 9.1% in the 3rd quarter. Commerce Bank now owns 9,471 shares of the company’s stock worth $633,000 after acquiring an additional 787 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Moderna in the 3rd quarter valued at about $1,515,000. Knuff & Co LLC boosted its position in shares of Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after acquiring an additional 244 shares during the last quarter. Finally, Quest Partners LLC increased its position in shares of Moderna by 239.8% in the third quarter. Quest Partners LLC now owns 4,567 shares of the company’s stock worth $305,000 after purchasing an additional 3,223 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 0.1 %

NASDAQ:MRNA traded up $0.04 on Wednesday, reaching $37.33. 1,421,693 shares of the stock traded hands, compared to its average volume of 4,755,108. The company’s fifty day simple moving average is $56.98 and its 200 day simple moving average is $95.46. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $14.37 billion, a price-to-earnings ratio of -6.41 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.39) earnings per share. Equities analysts predict that Moderna, Inc. will post -9.43 EPS for the current fiscal year.

Insider Transactions at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 2,930 shares of company stock worth $217,170 in the last quarter. Company insiders own 15.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Piper Sandler reissued an “overweight” rating and issued a $69.00 price target (down previously from $115.00) on shares of Moderna in a research note on Monday. Leerink Partners reduced their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. TD Cowen dropped their price target on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research note on Friday, September 13th. Berenberg Bank assumed coverage on Moderna in a research report on Tuesday. They set a “hold” rating and a $42.00 price objective on the stock. Finally, JPMorgan Chase & Co. dropped their target price on Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a research report on Monday, November 4th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $84.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.